Warwick Smith, director general of the British Generic Manufacturers Association (BGMA), discusses the potential impact of Brexit and recent policy changes on the British generics industry and extols the benefits of inter-stakeholder collaboration.
Entering 2018, three key themes affecting the British generics industry are Brexit, a new life science industry policy, and the medicines value program. Is this a very particular moment or is it just business as usual?
"It's important to recognize that generic competition does not only reduce cost and increase patient access to medicines, it spurs innovation."
